US Ahead Of EU On ‘Out-Of-Spec’ Advanced Therapy Products, Says Biotech

 
• By Eliza Slawther
  
It is easier to provide out-of-specification advanced therapies in US clinical trials than in European ones, a biotech expert says (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Cell & Gene Therapies

More from Advanced Technologies